oral semaglutide 50 mg obesity oasis 1 nejm 2023 Obesity: once-daily GLP-1 orforglipron shows clinically meaningful weight loss 𝗠𝗼𝘀𝘁 𝗽𝗲𝗼𝗽𝗹𝗲 𝗮𝘀𝘀𝘂𝗺𝗲 𝘁𝗵𝗲 𝘄𝗲𝗶𝗴𝗵𝘁

Laming et al., 2000

Semaglutide, a GLP-1 receptor agonist, simulates the functions of the bodys natural incretin hormones, which help to lower blood sugar levels after a meal

Here are the therapeutic opportunities now coming into focus: Cardiovascular protection: GLP-1 drugs have been shown to reduce the risk of major cardiovascular events such as heart attacks and strokes

What About Lab Work and Follow-up Costs

The unique challenge in treating patients suffering from both conditions lies in the necessity for a coordinated approach that takes into account the interplay between metabolic and mental health issues

Sources: